1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl l):S1-266
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1-150
3. Tsai WC, Wu HY, Peng YS et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore) 2016;95(11):e3013. doi: 10.1097/MD.0000000000003013
4. Shen Y, Cai R, Sun J et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine 2017;55(1):66-76. doi: 10.1007/sl2020-016-1014-6
5. Chang AR, Grams ME, Ballew SH et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 2019;364:k5301. doi: 10.1136/bmj.k5301
6. Nitsch D, Grams M, Sang Y et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013;346:ß24. doi: 10.1136/bmj.f324
7. See EJ, Jayasinghe K, Glassford N et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int 2019;95(1):160-172. doi: 10.1016/j.kint.2018.08.036
8. Rashidbeygi E, Safabakhsh M, Delshad Aghdam S et al. Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: Evidence from a meta-analysis on 10,603,067 subjects from 57 studies. Diabetes Metab Syndr 2019;13(l):830-843. doi: 10.1016/j.dsx.2018.12.006
9. Xia J, Wang L, Ma Ζ et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant 2017;32(3):475-487. doi: 10.1093/ndt/gfw452
10. Garofalo C, Borrelli S, Pacilio Μ et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. Am J Kidney Dis 2016;67(l):89-97. doi: 10.1053/j.ajkd.2015.08.027
11. Shang W, Li L, Ren Y et al. History of kidney stones and risk of chronic kidney disease: ameta-analysis. Peer J 2017;5:e2907. doi: 10.7717/peerj.2907
12. Musso G, Gambino R, Tabibian JH et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11(7):el001680. doi: 10.1371/journal.pmed.l001680
13. Mantovani A, Zaza G, Byrne CD et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism 2018;79:64-76. doi: 10.1016/j.metabol.2017.11.003
14. Yu X, Yuan Z, Lu Η et al. Relationship between birth weight and chronic kidney disease: evidence from systematics review and two-sample Mendelian randomization analysis. Hum Mol Genet 2020;29(13):2261-2274. doi: 10.1093/hmg/ddaa074
15. Major RW, Cheng MRI, Grant RA et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One 2018;13(3):e0192895. doi: 10.1371/journal.pone.0192895
16. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3
17. Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3
18. Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2
19. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005
20. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellirus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012;172(10):761-9. doi: 10.1001/archinternmed.2011.2230
21. Alizadeh S, Esmaeili H, Alizadeh Μ et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab 2019;63(4):427-437. doi: 10.20945/23593997000000149
22. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4(10):1565-74. doi: 10.2215/CJN.02250409
23. Schwasinger-Schmidt ТЕ, Elhomsy G, Paull-Forney BG. Impact of a Community-Based Weight Loss Program on Renal Function. Cureus 2020;12(5):e8101. doi: 10.7759/cureus.8101
24. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6(10):2364-73. doi: 10.2215/CJN.02180311
25. Staplin N, Haynes R, Herrington WG et al. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2016;68(3):371-80. doi: 10.1053/j.ajkd.2016.02.052